All medicines may have potential side effects but they are
usually minor. Ventolin HFA Aerosol’s minor side effects include coughing,
headache, nervous feeling, inflamed sinus, sore throat, tremor, unusual taste
in one’s mouth and finding it hard to fall asleep.
Medical attention should be sought right away if one experiences any severe side effects of Ventolin HFA aerosol. These maybe reflected in allergic reactions indicated by rash, itching, difficult breathing, a tight feeling in the chest, swollen mouth, face and tongue. If one feels chest pain and experiences an irregular heartbeat, severe headache and dizziness or worsened trouble when breathing, the doctor should be informed immediately.
Ventolin HFA side effects may be triggered by or somehow connected to paradoxical bornchospasms, cardiovascular effects, immediate hypersensitivity reactions, or hypokalemia.
Clininal trials offer adverse reaction rates and are conducted under conditions that vary greatly and those rates cannot be compared to other medication’s rates and do not reflect the rates that get observed in practice.
Over the course of twelve weeks, a randomized double blind
study took place in 610 asthmatic patients of various ages.
During the study, the Ventolin HFA got compared with a CFC 11/12 propelled Albuterol inhalator and an HFA-134a placebo inhaler. The incidence of adverse reaction for the Ventolin HFA and the Albuterol inhaler were pretty much comparable. The group that used Ventolin HFA had a three percent greater rate of adverse reaction and it was even more frequent than that of the group that used the placebo inhaler.
A pediatric clinical study in infants with asthma showed an adverse reaction similar to the one usually associated with adolescent and adult patients.
Over the course of three studies, the scientists came to the conclusion that the efficacy of Ventolin HFA cannot be established in the group of patients that includes children between birth and four years of age, and therefore its safety for this group of patients suffering from asthma cannot be established.
The pediatric population of infants under four years old has a safety
profile that is highly comparable to the safety profile of the patients that
belong to the geriatric, adult and adolescent patients. The adverse reaction rates were significantly greater in the group of patients under four years old.
Higher incidence rates were present in all different treatment groups, including the placebo inhalers. Adverse reactions usually include infections of the upper respiratory tract, pyrexia, and tachycardia.